Table 2.
Results (%) obtained with each in vitro technique in each group of patients.
| Patient classification | TST | QFN-G-IT | IP-10 direct plasmaa | IP-10 DPSb |
|---|---|---|---|---|
| Active TB (n = 12) | ||||
| Positive | 7 (100.0) | 12 (100.0) | 11 (91.7) | 9 (75.0) |
| Negative | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) |
| Indeterminatea | — | 0 (0.0) | 0 (0.0) | 3 (25.0) |
| Contacts (n = 68) | ||||
| Positive | 61 (98.4) | 47 (69.1) | 41 (60.3) | 33 (48.5) |
| Negative | 1 (1.6) | 21 (30.9) | 27 (39.7) | 32 (47.1) |
| Indeterminatea | — | 0 (0.0) | 0 (0.0) | 3 (4.4) |
| LTBI (n = 47) | ||||
| Positive | 41 (100.0) | 47 (100.0.0) | 39 (83.0) | 33 (70.2) |
| Negative | 0 (0.0) | 0 (0.0) | 8 (17.0) | 11 (23.4) |
| Indeterminatea | — | 0 (0.0) | 0 (0.0) | 3 (6.4) |
| UC (n = 21) | ||||
| Positive | 20 (95.2) | 0 (0.0) | 2 (9.5) | 0 (0.0) |
| Negative | 1 (4.8) | 21 (100.0) | 19 (90.5) | 21 (100.0) |
| Indeterminatea | — | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Overall (n = 80) | ||||
| Positive | 68 (98.6) | 59 (73.8) | 52 (65.0) | 42 (52.5) |
| Negative | 1 (1.4) | 21 (26.2) | 28 (35.0) | 32 (40.0) |
| Indeterminatea | — | 0 (0.0) | 0 (0.0) | 6 (7.5) |
aCut-offs: Ag-Nil = 1.3 ng/ml, Mit-Nil = 0.1 ng/ml. bCut-offs: Ag-Nil = 57.4 pg/2discs, Mit-Nil = 17.8 pg/2discs. UC: uninfected controls.